Presentation is loading. Please wait.

Presentation is loading. Please wait.

A loading dose decreases the time to achieve the target concentration.

Published byἸωσῆς Αντωνόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "A loading dose decreases the time to achieve the target concentration."— Presentation transcript:

1 A loading dose decreases the time to achieve the target concentration.
A loading dose decreases the time to achieve the target concentration. When the plasma t1/2 is prolonged (for example, because of kidney disease), the time to reach steady state or the target concentration increases proportionally. Administration of a loading dose reduces the time to achieve the therapeutic plasma concentration, and in this simulation the loading dose is double the maintenance dose. Darren M. Roberts et al. CJASN 2018;13: ©2018 by American Society of Nephrology

Download ppt "A loading dose decreases the time to achieve the target concentration."

Similar presentations

Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel.

Pharmacokinetic Modeling and Simulation of Procainamide and N-Acetylprocainamide in a Patient Receiving Continuous Renal Replacement Therapy: A Novel.
Proinflammatory effects of iron sucrose in chronic kidney disease

Proinflammatory effects of iron sucrose in chronic kidney disease
Conceptual model of the natural history of diabetic kidney disease.

Conceptual model of the natural history of diabetic kidney disease.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Conceptual model of the course of chronic kidney disease (CKD).

Conceptual model of the course of chronic kidney disease (CKD).
Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.

Representative transaxial thin computed tomography (CT) sections at mid, mid-low, and low levels of the heart from a control subject (left) showing normal.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
Patient 2, who presented with delirium as a result of a plasma sodium concentration (PNa) of 115 mmol/L and alcohol withdrawal, was given multiple doses.

Patient 2, who presented with delirium as a result of a plasma sodium concentration (PNa) of 115 mmol/L and alcohol withdrawal, was given multiple doses.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.

Distribution of podocyte gene mutations in patients with genetic congenital nephrotic syndrome (CNS) and steroid–resistant nephrotic syndrome (SRNS). Distribution.
Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Mean (SD) weekly hemoglobin level (g/dl) and mean (SD) weekly epoetin dose by body weight (U/kg per week) were similar between epoetin alfa-epbx and epoetin.

Similar presentations

Ads by Google